Clinical Pipeline

Showing 381 articles
Business

MGM Resorts Bets Big on Nevada Solar, But Can Green Power Spark a Stock Revival?

MGM Resorts International is powering its Las Vegas Strip operations with a major new solar and battery storage deal. This strategic shift toward renewables comes as the company's stock shows mixed signals, trading below some fair value estimates yet at a high earnings multiple, leaving investors to weigh long-term sustainability against immediate financial metrics.

Business

Ondas Secures Coveted Pentagon 'Blue List' Approval for Optimus Drone, Fueling Investor Debate on Valuation

Ondas Holdings' flagship Optimus drone system has received the Defense Contract Management Agency's critical 'Blue List' certification, clearing it for broader U.S. defense and national security deployment. The milestone has ignited a surge in the company's stock while prompting analysts to scrutinize its long-term path to converting regulatory approval into sustainable revenue.

Business

Aeris Resources Surges on Strong Production, Debt Clearance; But Is the Rally Overextended?

Aeris Resources (ASX:AIS) shares have soared following a robust December quarter report featuring record copper-equivalent output and full repayment of a A$50 million debt facility. The operational momentum has fueled a dramatic 350% one-year shareholder return, yet analysts are divided on whether the stock's current price accurately reflects its underlying value or has overshot fundamentals.

Business

AI and Academia Reshape San Francisco's Showplace Square, Signaling a New Chapter for Office Market

Once a symbol of tech retrenchment, San Francisco's Showplace Square is undergoing a profound transformation. Major leases by AI firms Together AI and Physical Intelligence, coupled with Vanderbilt University's planned campus, are redefining the neighborhood as a nexus for technology, education, and innovation, offering a significant boost to the city's office recovery narrative.

Business

U.S. Bets Big on Homegrown Rare Earths, Challenging Lynas Amid Leadership Shift

Major U.S. federal investment to build a domestic rare earth supply chain emerges as a direct competitive threat to Lynas Rare Earths, coinciding with the planned retirement of its long-serving CEO Amanda Lacaze. The developments test the Australian miner's strategic position in a market defined by geopolitical tensions and supply security concerns.